CoChat

The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.

Development of an inducible anti-VEGF rAAV gene therapy strategy for the treatment of wet AMD

Open access

Abstract

Vascular endothelial growth factor (VEGF) is a key mediator in the development and progression of choroidal neovascularization (CNV) in patients with wet age-related macular degeneration (AMD). As a consequence, current treatment strategies typically focus on the administration of anti-VEGF agents, such as Aflibercept (Eylea), that inhibit VEGF function. While this approach is largely successful at counteracting CNV progression, the treatment can require repetitive (i.e. monthly) intravitreal injections of the anti-VEGF agent throughout the patient’s lifetime, imposing a substantial financial and medical burden on the patient. Moreover, repetitive injection of anti-VEGF agents over a period of years may encourage progression of retinal and choroidal atrophy in patients with AMD, leading to a decrease in visual acuity. Herein, we have developed a single-injection recombinant adeno-associated virus (rAAV)-based gene therapy treatment for wet AMD that prevents CNV formation through inducible over-expression of Eylea. First, we demonstrate that by incorporating riboswitch elements into the rAAV expression cassette allows protein expression levels to be modulated in vivo through oral supplementation on an activating ligand (e.g. tetracycline). We subsequently utilized this technology to modulate the intraocular concentration of Eylea following rAAV delivery, leading to nearly complete (p = 0.0008) inhibition of clinically significant CNV lesions in an established mouse model of wet AMD. The results shown in this study pave the way for the development of a personalized gene therapy strategy for the treatment of wet AMD that is substantially less invasive and more clinically adaptable than the current treatment paradigm of repetitive bolus injections of anti-VEGF agents.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41598-018-29726-7

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Evaluation of the effect of copy number on riboswitch dynamics. (A) Schematic representation of constructs generated through insertion of 1, 2, 3 or 4 copies of each riboswitch into the 3′-UTR and depiction of the mechanism of an ‘ON-type’ riboswitch in the presence or absence of activating ligand. hPGK; human phosphoglycerate kinase promoter, p(A); polyadenylation signal, SV40; Simian vacuolating virus 40 promoter, RS; riboswitch. Dual luciferase assay in HEK293T cells with (grey bars) or without (blue bars) the activating ligand at saturating levels for cells transfected with 1,2,3 or 4 copies of (B) K19, (C) L2Bulge9, (D) L2Bulge18tc, (E) GuaM8HDV or (F) TC45; n = 3 for all groups, green arrow represents the optimal copy number. Values are normalized to unmodified Firefly luciferase activity with standard error shown.
Figure 1 Evaluation of the effect of copy number on riboswitch dynamics. (A) Schematic representation of constructs generated through insertion of 1, 2, 3 or 4 copies of each riboswitch into the 3′-UTR and depiction of the mechanism of an ‘ON-type’ riboswitch in the presence or absence of activating ligand. hPGK; human phosphoglycerate kinase promoter, p(A); polyadenylation signal, SV40; Simian vacuolating virus 40 promoter, RS; riboswitch. Dual luciferase assay in HEK293T cells with (grey bars) or without (blue bars) the activating ligand at saturating levels for cells transfected with 1,2,3 or 4 copies of (B) K19, (C) L2Bulge9, (D) L2Bulge18tc, (E) GuaM8HDV or (F) TC45; n = 3 for all groups, green arrow represents the optimal copy number. Values are normalized to unmodified Firefly luciferase activity with standard error shown.CC BY · PubMed Central
Figure 2 Assessment of riboswitch dosing kinetics in HEK293T cells. Normalized GFP fluorescence and representative GFP (inducible) and mCherry (non-inducible) images at varying concentrations of activating ligand for (A) K19, (B) L2Bulge9, (C) L2Bulge18tc, (D) GuaM8HDV and (E) TC45. Dynamic range is represented as fold-change. n = 3, **p > 0.01, ***p > 0.001, ****p > 0.001, One-Way ANOVA with Tukey’s post-hoc test. For each group, respective fluorescent channels were recorded with constant exposure and gain; scale bars = 50 μM.
Figure 2 Assessment of riboswitch dosing kinetics in HEK293T cells. Normalized GFP fluorescence and representative GFP (inducible) and mCherry (non-inducible) images at varying concentrations of activating ligand for (A) K19, (B) L2Bulge9, (C) L2Bulge18tc, (D) GuaM8HDV and (E) TC45. Dynamic range is represented as fold-change. n = 3, **p > 0.01, ***p > 0.001, ****p > 0.001, One-Way ANOVA with Tukey’s post-hoc test. For each group, respective fluorescent channels were recorded with constant exposure and gain; scale bars = 50 μM.CC BY · PubMed Central
Figure 3 Riboswitch mediated gene modulation in the mouse retina following rAAV gene delivery. Four weeks following intravitreal delivery, baseline GFP and mCherry images were recorded. Seven days following baseline imaging mice received a 10 mg/kg gavage of the activating ligand and were re-imaged 2 hours post-gavage. Representative GFP (inducible) and mCherry (non-inducible) images for (A) K19, (B) L2Bulge9, (C) L2Bulge18tc, (D) GuaM8HDV and (E) TC45 are shown; Scale bars = 200 nm. (F) Quantified post-treatment GFP fluorescence normalized to mCherry fluorescence and displayed as a change from baseline levels (set at 100%). n = 3–7, *p > 0.05, paired t test.
Figure 3 Riboswitch mediated gene modulation in the mouse retina following rAAV gene delivery. Four weeks following intravitreal delivery, baseline GFP and mCherry images were recorded. Seven days following baseline imaging mice received a 10 mg/kg gavage of the activating ligand and were re-imaged 2 hours post-gavage. Representative GFP (inducible) and mCherry (non-inducible) images for (A) K19, (B) L2Bulge9, (C) L2Bulge18tc, (D) GuaM8HDV and (E) TC45 are shown; Scale bars = 200 nm. (F) Quantified post-treatment GFP fluorescence normalized to mCherry fluorescence and displayed as a change from baseline levels (set at 100%). n = 3–7, *p > 0.05, paired t test.CC BY · PubMed Central
Figure 4 Persistent dosing improves dynamic range in smCBA.GFP-1×-TC45 and smCBA.GFP-3×-L2Bulge18tc treated mice. Following baseline imaging, mice were provided with tetracycline diet ad libitum for 7 days at a concentration of 50 g/kg. Representative GFP and mCherry baseline and post-treatment fluorescent images of mice injected with (A) smCBA.GFP-1×-TC45 or (B) smCBA.GFP-3×-L2Bulge18tc. (C) Quantified post-treatment GFP fluorescence normalized to mCherry fluorescence and represented as percentage of baseline GFP fluorescence. n = 6, **p > 0.01, paired t test. (D) Normalized GFP protein levels in smCBA.GFP-1×-TC45 or smCBA.GFP-3×-L2Bulge18tc injected mice receiving tetracycline or standard diet for 4 weeks. n = 3, *p > 0.05, unpaired t test.
Figure 4 Persistent dosing improves dynamic range in smCBA.GFP-1×-TC45 and smCBA.GFP-3×-L2Bulge18tc treated mice. Following baseline imaging, mice were provided with tetracycline diet ad libitum for 7 days at a concentration of 50 g/kg. Representative GFP and mCherry baseline and post-treatment fluorescent images of mice injected with (A) smCBA.GFP-1×-TC45 or (B) smCBA.GFP-3×-L2Bulge18tc. (C) Quantified post-treatment GFP fluorescence normalized to mCherry fluorescence and represented as percentage of baseline GFP fluorescence. n = 6, **p > 0.01, paired t test. (D) Normalized GFP protein levels in smCBA.GFP-1×-TC45 or smCBA.GFP-3×-L2Bulge18tc injected mice receiving tetracycline or standard diet for 4 weeks. n = 3, *p > 0.05, unpaired t test.CC BY · PubMed Central
Figure 5 Effect of intraocular Eylea concentration on CNV lesion formation in a murine model of wet AMD. Leakage from CNV lesions was assessed 7 days following laser injury. Representative FA images taken 5 minutes after fluorescein injection for mice injected with either (A–C) rAAV2[MAX].smCBA-Eylea, (D–F) rAAV2[MAX].smCBA-Eylea-1×-TC45 + standard diet, (G–I) rAAV2[MAX].smCBA-Eylea-1×-TC45 + tetracycline diet or (J–L) PBS (n = 16–20 lesions per group). Images of 3 mice per group with red arrows indicating site of the laser injury. (M) Distribution of lesions graded independently by three masked scientists. n = 16–20 lesions per group, p < 0.0001, Chi-squared test. (N) Intraocular levels of non-complexed Eylea assayed by ELISA. n = 5 eyes per group, standard error displayed.
Figure 5 Effect of intraocular Eylea concentration on CNV lesion formation in a murine model of wet AMD. Leakage from CNV lesions was assessed 7 days following laser injury. Representative FA images taken 5 minutes after fluorescein injection for mice injected with either (A–C) rAAV2[MAX].smCBA-Eylea, (D–F) rAAV2[MAX].smCBA-Eylea-1×-TC45 + standard diet, (G–I) rAAV2[MAX].smCBA-Eylea-1×-TC45 + tetracycline diet or (J–L) PBS (n = 16–20 lesions per group). Images of 3 mice per group with red arrows indicating site of the laser injury. (M) Distribution of lesions graded independently by three masked scientists. n = 16–20 lesions per group, p < 0.0001, Chi-squared test. (N) Intraocular levels of non-complexed Eylea assayed by ELISA. n = 5 eyes per group, standard error displayed.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 49 references

Cited by

See all 65

Metadata

Authors
Reid, C. A., Nettesheim, E. R., Connor, T. B., & Lipinski, D. M.
Affiliations
Medical College of Wisconsin (US)
Corresponding author
Lipinski, Daniel M.
Venue
Scientific Reports
Published
2018-08-06
Volume
8
Issue
1
Pages
11763-11763
ISSN
2045-2322 (ISSN-L)
OpenAlex
W2887127418
Cited by
65
References
49
Citations by year
2026: 6 · 2025: 6 · 2024: 8 · 2023: 12 · 2022: 11 · 2021: 8 · 2020: 8 · 2019: 6
FWCI
5.53
Type
journal article
Language
en
Open access
Licence
Locations
  • Scientific Reports (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
U.S. Department of Health &amp; Human Services | NIH | National Eye Institute (P30 EY001931-37)
Topics
  • Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
  • Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
Keywords
neovascular age-related macular degeneration, choroidal neovascularization, recombinant adeno-associated virus, aflibercept, riboswitches, inducible gene expression, tetracycline, intravitreal gene delivery
MeSH terms
Dependovirus, Animals, Enzyme-Linked Immunosorbent Assay, Female, Humans, Mice, Inbred C57BL, Software, Genetic Therapy, Microscopy, Confocal, Choroidal Neovascularization, Vascular Endothelial Growth Factor A, Mice, Wet Macular Degeneration, HEK293 Cells, Riboswitch

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Development of an inducible anti-VEGF rAAV gene therapy strategy for the treatment of wet AMD. https://app.cochat.ai/papers/10.1038/s41598-018-29726-7
The paper
Reid, C. A., Nettesheim, E. R., Connor, T. B., & Lipinski, D. M. (2018). Development of an inducible anti-VEGF rAAV gene therapy strategy for the treatment of wet AMD. Scientific Reports. https://doi.org/10.1038/s41598-018-29726-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.